<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749680</url>
  </required_header>
  <id_info>
    <org_study_id>PD-Silencia-01-CL</org_study_id>
    <nct_id>NCT04749680</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy and Tolerability of APD Treatment With Different PD Cyclers</brief_title>
  <official_title>Comparison of Efficacy and Tolerability of APD Treatment With Different PD Cyclers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Winicker Norimed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>James Motta, Clinical Research Associate (CRA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has been designed in order to investigate the performance and safety of the new&#xD;
      Silencia PD cycler including the Silencia tubing system in comparison to the PD-Night and&#xD;
      Homechoice PD cycler which are both well-established PD cyclers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective, controlled, multicentre, interventional</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Kt/V urea</measure>
    <time_frame>at the beginning and end of clinical phase 1 and 2 (each clinical phase is 14 days)</time_frame>
    <description>Measurement of solute removal during peritoneal dialysis focuses on urea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achieving Kt/Vurea ≥ 1.7</measure>
    <time_frame>at the beginning and end of clinical phase 1 and 2 (each clinical phase is 14 days)</time_frame>
    <description>Measurement of solute removal during peritoneal dialysis focuses on urea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean daily ultrafiltration (UF)</measure>
    <time_frame>at the beginning and end of clinical phase 1 and 2 (each clinical phase is 14 days)</time_frame>
    <description>Daily ultrafiltration reached by the Patient with APD</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Renal Failure</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Peritoneal dialysis PD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 2 weeks either with the comparators PD-Night or Homechoice PD cycler depending on the previous treatment (clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PD cycler Silencia</intervention_name>
    <description>Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).</description>
    <arm_group_label>Peritoneal dialysis PD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed and dated by study patient and investigator/authorised&#xD;
             physician&#xD;
&#xD;
          -  CKD patients being treated with APD for at least 3 months&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  Body weight ≥ 40 kg&#xD;
&#xD;
          -  Fluid status regularly monitored with Body Composition Monitor (BCM)&#xD;
&#xD;
          -  Patients planned to change to the Silencia PD cycler&#xD;
&#xD;
          -  Proper functioning catheter&#xD;
&#xD;
          -  Intraperitoneal Pressure (IPP) ≤ 18 cm H2O for the maximum of TAVO parameter&#xD;
             &quot;permitted patient volume&quot;&#xD;
&#xD;
          -  Ability to understand the nature and requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have any condition prohibiting the use of BCM, like patients with major&#xD;
             amputations (e.g. lower leg)&#xD;
&#xD;
          -  Patients receiving polyglucose containing PD solution&#xD;
&#xD;
          -  Any conditions which could interfere with the patient's ability to comply with the&#xD;
             study&#xD;
&#xD;
          -  Patients who suffer from peritonitis/exit site infection during the last 4 weeks&#xD;
&#xD;
          -  Women of childbearing age without effective means of contraception, pregnancy&#xD;
             (pregnancy test will be conducted at start and end of study) or lactation period&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Participation in an interventional clinical study during the preceding 30 days&#xD;
&#xD;
          -  Previous participation in the same study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Machuca, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fresenius Medical Care Chile S.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuela Stauss-Grabo, Dr</last_name>
    <phone>+49 6172 608</phone>
    <phone_ext>5248</phone_ext>
    <email>Manuela.Stauss-Grabo@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana De los Ríos</last_name>
    <phone>+49 6172 608</phone>
    <phone_ext>2362</phone_ext>
    <email>Tatiana.De-Los-Rios@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nephocare La Serena</name>
      <address>
        <city>La Serena</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Morales, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nephocare Independencia</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rubén Torres, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nephocare Providencia</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Flores, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nephocare San Bernardo</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Flores, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Automated peritoneal dialysis (APD)</keyword>
  <keyword>PD cyler</keyword>
  <keyword>Renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

